TNF and melanoma: Furthermore, to evaluate the impact of TNF-dependent signaling on the evolution of the plasma sphingolipidome between baseline and week 6, we compared the sphingolipid patterns in the plasma of advanced melanoma patients treated with ipilimumab and nivolumab (i.e., bi-therapy) from the MELANFα (NCT03348891) clinical trial, with those measured in the TICIMEL clinical trial (NCT03293784), in which patients were co-administered with ipilimumab, nivolumab and anti-TNF (certolizumab or infliximab) (i.e., tri-therapy).